הפודקאסטים הטובים ביותר ב-Biopharma (2024)

1
The M&A Pool Set to Accelerate Biotech Innovation 13:51

15d ago13:51

13:51

Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.…

1
pcd pharma 3:08

26d ago3:08

3:08

Explore the intricate world of PCD (Propaganda Cum Distribution) Pharma with our comprehensive guide.על ידי Medroots Biopharma India

1
How PIPEs finally unblocked biotech’s funding flows 17:36

20d ago17:36

17:36

The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been univ…

1
Episode: 17 - Essential Program Management Considerations for Biopharma With Jamie Martin 22:56

1M ago22:56

22:56

In this episode of Evaluating Biopharma, host Ben Locwin and Jamie Martin, PMP, senior consultant at Black Diamond Networks, discuss the tips and tricks of successful program management. Martin shares his mental checklist of must-haves to ensure a successful start, techniques on what to do when things fall off-track, and the keys to continuous succ…

1
Episode: 16 - Brian Tham on Project Management and Continuous Improvement in Biopharma 21:21

1M ago21:21

21:21

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Brian Tham, principal consultant at Peregrine Bio, LLC, on how various projects are run in the pharmaceutical industry, how to improve the outcome and processes of projects, and how to continue improving processes and operational excellence. They also delve into the history of how…

1
Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back 12:58

1M ago12:58

12:58

U.S. healthcare desperately needs to cut costs and improve outcomes. There is no single solution, but three disruptive forces in the digital health space are speeding change – and adding up to a healthy outlook for HCIT. Sean Dodge, Healthcare Technology Analyst, joins the podcast to unpack some of his predictions on the most impactful forces affec…

1
Innovating Oncology Patient Experience with Data, Digital & Tech 32:47

1M ago32:47

32:47

In this episode of the Driving Digital in Biopharma podcast, Samer Ansari, Head of Data, Digital, and Technology at Takeda Oncology, joins Tom Lehmann, Global Head of Accenture Life Sciences R&D, to discuss the role of digital in creating exceptional HCP and patient experiences. Through their shared passion for data and tech and the importance of u…

1
Navigating Success Unveiling the Best PCD Pharma Franchise Company 2:57

2M ago2:57

2:57

Tune in to our podcast episode as we delve into the pharmaceutical realm, uncovering the industry's top PCD pharma franchise company. Explore the factors that define the best, from product range to support systems. Join the conversation with industry experts as we unravel the secrets to success in the PCD pharma franchise arena. Whether you're an e…

1
Will the Biotech Rebound Run into Pricing Policy Obstacles? 13:25

2M ago13:25

13:25

Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.…

1
Episode: 15 - Facing CMC Challenges in CDMO-Sponsor Relationships for Rare Disease Platforms with Nesredin Mussa 19:42

2M ago19:42

19:42

In this month’s episode of Evaluating Biopharma, host Ben Locwin speaks with Nesredin Mussa, PhD, president of Dynamica Biologics, about navigating the challenges of securing successful CDMO-sponsor relationships for a rare disease manufacturing and testing paradigm, the key contributing factors that may pose within the partnership between the spon…

1
Few IPOs but plenty of follow-on for biotech in 2023 23:35

3M ago23:35

23:35

After a year of stark contrasts in the public and private equity markets for healthcare, 2024 is shaping up to be another mixed outlook. While biotech continues to bolster the market, albeit more in follow-on offerings than IPOs, and HCIT and healthcare services have tailwinds, the medtech and value-based care subsectors have challenges as well as …

1
U.S. Outlook: Will the US economy achieve a soft landing in 2024? 26:28

4M ago26:28

26:28

As the U.S. economy shows positive signs for growth, inflation, and interest rates in 2024, RBC Capital Markets’ RBC Capital Markets’ Michael Reid, Blake Gwinn, Vito Sperduto and Larry Grafstein analyze the challenges posed by consumer spending, political gridlock, and quantitative tightening. This episode was originally published on RBC's Strategi…

1
Pharma Pioneers: Navigating Excellence with the Best PCD Pharma Company 6:33

4M ago6:33

6:33

Discover the keys to success in the pharmaceutical sector by listening to our podcast, which features the Best PCD Pharma Company. Explore the tactics, ideas, and moral behavior that make these business titans unique. Come have enlightening discussions with influential individuals as we examine the ever-changing Pharma Franchise market and the dedi…

1
Inside the Pharma Franchise World: Navigating Opportunities with Medroots Bio Pharma 5:37

5M ago5:37

5:37

Discover the ever-changing world of pharmaceutical franchise opportunities with us on this insightful podcast episode. Learn about the tactics, difficulties, and accomplishments of Medroots Bio Pharma, a prominent figure in the sector. Discover the nuances of pharmaceutical franchises, the world of healthcare entrepreneurship, and how to succeed in…

1
Raising Venture Capital: A New Playbook for A New Era in Biotech 36:19

5M ago36:19

36:19

In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal stru…

1
Episode: 14 - Strategies and Approaches for Process Intensification With Dr. Stefan Schmidt 16:08

5M ago16:08

16:08

rocess intensification can be an overwhelming experience. In this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about strategies and approaches that can help you understand and figure out how to navigate process intensification. Schmidt discusses ways to produce consistent results while using di…

1
A modern balancing act: Harmonizing digital, data and traditional ways of working 43:10

6M ago43:10

43:10

In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, speaks to Chris Braithwaite, Global Head of Drug Development, Digital and IT Novartis. Achieving digital transformation requires a delicate balance between traditional methods, rapidly emerging technology, and human decision-making. Chris encourages a shift in perspective…

1
ECM: Robust End to Year, Despite Previous Volatility 31:24

6M ago31:24

31:24

As RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of Healthcare Equity Capital Markets explore how the firms who succeed in an especially dynamic market will be those willing to embrace new ways of thinking about unlocking value.על ידי RBC Capital Markets

1
Episode: 13 - Identifying Impurities In Gene Therapy With Santoshkumar Khatwani 19:38

6M ago19:38

19:38

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Santoshkumar Khatwani, Director – Analytical Development, Late-Stage CMC Analytical Team Lead at Sangamo Therapeutics, about impurities in gene therapy processes and the ways to identify them. Khatwani discusses how to determine if these impurities are from the product, the proces…

1
Medroots Bio Pharma Unlocks Opportunities in Healthcare 4:48

7M ago4:48

4:48

Explore the dynamic world of PCD Pharma Franchise in our podcast series. Dive into the pharmaceutical industry's entrepreneurial opportunities, success stories, and expert insights. Discover how to thrive as a PCD franchise partner, the latest healthcare trends, and the path to building a thriving pharmaceutical business. Join us for a dose of indu…

1
Biotech Halftime Report: A Winding Road Ahead 17:26

7M ago17:26

17:26

Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023. This episode was originally broadcast on Industries in Motion, the RBC podcast.על ידי RBC Capital Markets

1
Episode: 12 - The Risks and Rewards of Speed-to-IND Strategies With Susan Jones 19:32

7M ago19:32

19:32

What are some strategies that companies can use to get to IND filing quickly? In this brand new conversation, Evaluating Biopharma podcast host Ben Locwin discusses the risks and rewards of speed-to-IND strategies with Susan Jones, Chief Technology Officer at Tourmaline Bio. Susan delves into her 30 years of experience in the biotech industry, how …

1
The Urgent Need to Address the Youth Mental Health Landscape 28:06

8M ago28:06

28:06

U.S. soccer legends and World Cup champions Briana Scurry and Dr. Sara Hess joined Andrew Callaway, Global Head of Healthcare Investment Banking at RBC Capital Markets, at this year’s RBC Global Healthcare Conference.על ידי RBC Capital Markets

1
Episode: 11 - Cell Therapy Strategies: Preparing for Commercial Manufacturing of an Autologous Cell Therapy 21:49

8M ago21:49

21:49

In this episode of Evaluating Biopharma, host Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Jonathan Tsang, Senior Director, Manufacturing Sciences & Technology at Kite Pharma, who shares his experiences and provides advice on how autologous cell therapy companies can better prepare for commercial manufactur…

1
Website Traffic Reveals Biopharma Sales Trends 10:39

9M ago10:39

10:39

A new RBC ElementsTM report, “Insights from the BioWeb,” looks at the predictive potential of website traffic as a means to uncover underappreciated market trends and sales insights. Mark Odendahl, Head of US Capital Markets Research, is joined by Brian Abrahams, Head of Biotechnology at RBC Capital Markets, to discuss the report’s findings.…

1
When to Call it Quits: VCs Making Tough Decisions in a Tough Market 32:02

9M ago32:02

32:02

While the public biotech markets remain volatile, VCs continue to raise new funds. Are we witnessing a renaissance in the private capital markets? The bankruptcy rate of biotechs is historically among the lowest of US publicly traded companies, however, companies are failing and there is still a widely held belief that too many biotech companies ar…

1
Episode: 10 - Gene Therapy Analytics: How to Make the Right CMC Investments for Your Business 22:43

9M ago22:43

22:43

In this episode of Evaluating Biopharma, Mike Kelly, Senior Vice President at Atsena Therapeutics, shares his experiences and provides his advice on how your company can make proper CMC investments to reduce risk and maximize ROI, including: the make or buy decision, ensuring CMC investment to provide regulators what they need, scalability consider…

1
How Biotech M&A is Redefining the Strategic Landscape 25:53

10M ago25:53

25:53

Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets A…

1
Episode: 9 - Gene Therapy Analytics: Identifying and Overcoming CMC Challenges in Gene Therapy 24:32

10M ago24:32

24:32

In this episode of Evaluating Biopharma, Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Susan D'Costa, Chief Technology Officer at Alcyone Therapeutics, who shares her experiences and provides advice on how your company can identify and overcome CMC challenges in gene therapy, including: understanding and mon…

1
Healthcare Should Get Ready for ‘Fast and Furious’ M&A 26:06

11M ago26:06

26:06

Hear from Vito Sperduto, RBC’s Co-Head of Global M&A, and his panel of RBC Capital Markets’ expert bankers on how large healthcare firms with strong balance sheets are putting cash to work — driving a ‘fast and furious’ surge of M&A activity in the second half of the year and into 2024. Learn why healthcare momentum is building and how smaller deal…

1
Innovation and Growth: Key Ingredients to Healthcare M&A 24:18

11M ago24:18

24:18

Compressed valuations, heightened CEO confidence, and the desire to accelerate top-line growth and scale innovation are the key factors driving healthcare M&A in 2023. As deal activity starts to accelerate, our banking experts are asking, what’s next for the sector? Listen to Pathfinders in Biopharma to find out. This episode features insights from…

1
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point? 17:04

11M ago17:04

17:04

In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.על ידי RBC Capital Markets

1
Global Blood Therapeutics Commitment to Sickle-Cell Innovation 22:29

11M ago22:29

22:29

In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specif…

1
Design for the future and deliver progress over perfection 41:43

12M ago41:43

41:43

In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, talks with Michel Rider, VP Digital, Analytics and Performance at GSK. Michel reflects on their multi-year quest to modernize digital, data, and analytics capabilities across Development – sharing insights for achieving near-term wins while planning for the future. There …

1
Is This the Breakthrough Moment for Genetic Medicine? 17:25

1y ago17:25

17:25

Genetic medicine is poised to unlock more value for patients and investors due to disruptive technologies like mRNA, siRNA and gene editing. With an estimated 27 genetic medicines already approved, RBC’s biotechnology analyst Luca Issi explains how these technologies could be used next, and why companies able to combine the right choice of interven…

1
Episode: 8 - The Financial Impact of a Continuous Bioprocessing Strategy 20:08

1y ago20:08

20:08

Joseph Shultz, VP and technical head of biologics and vaccines at Resilience, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss the financial considerations biopharma companies face when implementing a continuous strategy. Shultz talks about the mindset of the senior leadership at…

1
Episode: 7 - Implementing an Efficient Allogeneic Cell Therapy Manufacturing Strategy 27:22

1y ago27:22

27:22

Marty Giedlin, vice president and head of technology operations at Senti Bio, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, to share his experiences and provide advice on how allogeneic cell therapy companies can implement better manufacturing strategies. He discusses understanding and managing man…

1
Rethink it: Digital is not a thing, digital is a means 47:58

1y ago47:58

47:58

In this episode of Driving Digital in Biopharma, host Tom Lehmann talks with Jason Bronfeld, Head of Product Development IT at Bristol-Myers Squibb, about the industry re-perceiving itself and capitalizing on the power of digital. When it comes to evolving ways of operating to an ever-better model for the future, a mindset shift is essential – digi…

1
Episode: 06 - Process Intensification: PAT, AI, ML to Support Intensified Bioprocessing 19:15

1y ago19:15

19:15

Arthi Narayanan, innovation team leader of pharma technical operations at Genentech, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss how process analytical technology, artificial intelligence, and machine learning support intensified bioprocessing and improve inefficiencies. Nar…

1
The Hidden Revolution Set to Turn US Healthcare on its Head 19:07

1y ago19:07

19:07

In the latest episode of Pathfinders, our Healthcare technology analyst Sean Dodge explores a quiet but accelerating revolution in the way US healthcare works – and the new breed of companies poised to benefit.על ידי RBC Capital Markets

1
Episode: 05 - Navigating Scale-Up Challenges in Protein Production 20:45

1+ y ago20:45

20:45

Parrish Galliher, an independent bioprocess consultant, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the context-dependent issues that arise when scaling-up protein production. Gallaher uses a case study involving scaling challenges in E. coli bioprocesses that produced a product at 50% pote…

1
Episode 4: Anticipating Disruptions: Identifying and Planning for Shortages 19:42

1+ y ago19:42

19:42

In the biopharma space, nearly every moving part is contingent upon a functioning supply chain. In this month’s episode, moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, speaks with Rich Musa, director and head of supply chain at Cipla Therapeutics, about anticipating supply chain disruptions and planning for sho…

1
The Big Picture for Biotech 21:49

1+ y ago21:49

21:49

In this latest episode, our head of biotech research Brian Abrahams shares a big picture analysis of the industry, outlining the long-term disruptions and opportunities ahead for biotech.על ידי RBC Capital Markets

1
2022 Life Sciences Tech Trends - The Metaverse Continuum for Supply Chain 23:27

1+ y ago23:27

23:27

In this episode, Tom Lehmann talks with Natasha Kelly, a data scientist within Accenture's Applied Intelligence Group who focuses on advanced analytic solutions in life sciences manufacturing and supply chain. Tom and Natasha discuss the 2022 Life Sciences Technology Vision through a supply chain lens, delving into how each of the report's four tre…

1
Why Biopharma Investment Requires a Different Mindset 22:52

1+ y ago22:52

22:52

In the latest episode of Pathfinders, Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, reveals why he’s feeling optimistic about M&A in biopharma and how leading in biotech investment and corporates needs visionary long-term thinking.על ידי RBC Capital Markets

1
2022 Life Sciences Tech Trends - The Metaverse Continuum for Biopharma R&D 14:19

1+ y ago14:19

14:19

In this episode, Tom Lehmann talks with Accenture’s Ross Wooddisse, Managing Director and Life Sciences R&D Lead in Europe, about the 2022 Life Sciences Technology Vision and what the Metaverse continuum means for Biopharma R&D. They discuss how science turns into medicine, a new generation of digital trial capabilities and the fundamental opportun…

1
Episode: 3 - Cell and Gene Therapy: Managing the ‘Build or Buy’ Decision 22:36

1+ y ago22:36

22:36

Dave Backer, founder of DB Biologics and former chief commercial officer at Oxford Biomedica, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the complex business and technological decisions companies face when navigating supply chain issues in the cell and gene therapy (CGT) market. Today’s co…

1
Episode: 2 - Operational Efficiencies: Lower Operational Costs by Reducing Clinical GMP Sampling 25:12

1+ y ago25:12

25:12

In this episode, Josefine Persson, Genentech associate director, and Ben Locwin, Black Diamond Networks vice president of project solutions, discuss how the cost of oversampling from clinical GMP runs versus development sources equates to high expenses and lost opportunities in moving a new project into GMP manufacturing. Persson also talks about t…

1
The Optimism Behind the Biopharma Market 25:49

1+ y ago25:49

25:49

In this episode, Dr. Chen Yu, Founder and Managing Partner at TCG X and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, discuss why they remain optimistic about biotech and what’s happening behind the scenes in public and private markets.על ידי RBC Capital Markets

1
Episode 000: Introducing the Evaluating Biopharma Podcast 2:07

1+ y ago2:07

2:07

Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary informati…

פודקאסטים ששווה להאזין

פודקאסטים בנושא Biopharma

פודקאסטים ששווה להאזין

מדריך עזר מהיר